Menu
Build the
Evidence That
Moves the Deal.
Nectid helps clinical-stage biotech companies determine what evidence
will cause a specific counterparty to fund, option, license, or advance
an asset—and then aligns business development, development strategy,
and capital around that decision.
Powered by TSCIP
Development designed backward from the transaction.
Confidential Intake
Evaluate an Asset
Tell us where the program stands and what decision you are preparing for.
Science identifies the opportunity.
Evidence defines what’s underwritable. Validation defines market need. Capital defines who funds the proof.
SCIENCE
Evidence
Capital
Transaction
Capital
Transaction
Capital
Transaction
The Problem
Good Science Does
Not Automatically Create a Transaction.
01
The biology is compelling.
02
Early clinical data are encouraging.
03
Pharma expresses interest.
04
But the transaction does not happen.
The Decision-Evidence Gap
A potential partner may require evidence the current program was never designed to produce.
The gap is rarely about whether the science is good. It is about whether a specific decision-maker can underwrite the remaining uncertainty.
E01
Monotherapy activity
E02
Combination attribution
E03
Additional safety exposure
E04
Evidence in another tumor state
E05
Defined regulatory path
E06
CMC readiness
E07
Specific proof points
Generating everything is expensive.
Generating the right evidence can change the asset.
TSCIP
Development Designed Backward From the Transaction.
TSCIP is Nectid's proprietary BD-led development platform. It starts from the decision a counterparty has to make and works backward into the development plan.
Traditional Development
- Mechanism
- Preclinical Data
- Mechanism
- Clinical Development
TSCIP
- Potential Counterparty
- Investment Decision
- Evidence Requirement
- Development Plan
- Source of Capital
“What study should we run next?”
What is the smallest credible evidence package that would change the next important Capital or partnering decision?
Rigorous Audit Matrix
What TSCIP Evaluates
A comprehensive 16-point diagnostic system across technology, strategic fit, IP, and transaction execution.
Pillar 01
Biology & Mechanism
Mechanistic Rationale
01_mechanistic_rationale.svg
Pillar 02
Biology & Mechanism
Tumor State Biology
02_tumor_state_biology.svg
Pillar 03
Biology & Mechanism
Independent Drug Activity
03_independent_drug_activity.svg
Pillar 04
Biology & Mechanism
Combination Attribution
04_combination_attribution.svg
Pillar 05
Strategy & Differentiation
Therapeutic Index
05_therapeutic_index.svg
Pillar 06
Strategy & Differentiation
Transferability Backbones
06_transferability_backbones.svg
Pillar 07
Strategy & Differentiation
Competitive Positioning
07_competitive_positioning.svg
Pillar 08
Strategy & Differentiation
Partner Substitution Risk
08_partner_substitution_risk.svg
Pillar 09
Strategy & Differentiation
Clinical Differentiation
09_clinical_differentiation.svg
Pillar 10
Execution & Timing
Regulatory Strategy
10_regulatory_strategy.svg
Pillar 11
Execution & Timing
Development Timing
11_development_timing.svg
Pillar 12
Execution & Timing
CMC Readiness
12_cmc_readiness.svg
Pillar 13
Strategy & Differentiation
Pharma Strategic Fit
13_pharma_strategic_fit.svg
Pillar 14
Execution & Timing
Evidence For Reengagement
14_evidence_for_reengagement.svg
Pillar 15
Commercial & Capital
Development Capital Requirements
15_development_capital_requirements.svg
Pillar 16
Commercial & Capital
Potential External Capital
16_potential_external_capital.svg
One Operating System
The TSCIP Operating Model
Science → Field Validation → Evidence → Capital → Transaction.
A transaction-oriented operating model connecting asset assessment directly to closing transactions. Click any phase to inspect the decision logic, gate criteria, and next best action.
ASSET
ASSESSMENT
Understand the asset, strengths, uncertainties, evidence gaps and capital
- Gate 01
- View ➜
COUNTERPARTY
MAPPING
Which specific companies could act, and on which dimension of strategic fit.
- Gate 02
- View ➜
Field BD
Validation
Direct engagement to learn what would actually change the counterparty's decision.
- Gate 03
- View ➜
Evidence
Architecture
The minimum credible evidence package required to cross the identified gate.
- Gate 04
- View ➜
Capital
Routing
Who should finance that evidence, and through which structure.
- Gate 05
- View ➜
Transaction
Execution
Carrying the validated thesis into a defined strategic transaction.
- Gate 06
- View ➜
Field BD Validation
BD Is Not the Final Step. It Is Part of Development.
Counterparty feedback is treated as development data. It defines the evidence gap, which defines the plan, which defines the capital required.
- What would cause the counterparty to advance?
- What additional evidence is required?
- What would cause the counterparty to fund development?
The Feedback Loop
- Counterparty feedback
- Evidence gap
- Development Plan
- Capital
- New evidence
- Counterparty re-engagement
Structure
Two Funnels. One Objective.
Funnel 01
Strategic Partnering
Identify companies for which the asset creates strategic value.
- Asset
- Counterparties
- Engagement
- Validation
- Transaction
Funnel 02
Evidence Financing
Identify who should finance the evidence required to unlock the transaction.
- Evidence Gap
- Capital Source
- Development
- Evidence
- Transaction
- Transaction
Decision Output
Advance, Modify, Hold & Defer
Every engagement resolves to a stated recommendation, with the reasoning made explicit.
Advance
Evidence and market validation justify continued investment.
Modify
The asset remains attractive, but the strategy needs to change.
Hold
Wait for a strategic, scientific or financing catalyst.
Defer
Incremental investment is unlikely to create adequate probability-adjusted return.
Capital discipline, not development for its own sake.
Who We Work With
Three Positions. One Framework.
Asset Holders
Turn Partner Interest Into an Actionable Development Strategy.
Convert informal pharma interest into a defined evidence requirement, a costed development plan and a funding route.
Pharma Partners
Find Assets Through the Evidence That Matters.
Evaluate opportunities against the proof points your committees actually underwrite, with the gaps stated openly.
Development-Capital Partners
Finance an Identified Evidence Gap.
Deploy capital against a specific, validated evidence requirement with a defined transaction pathway on the other side.
Track Record
Built From Transaction Experience.
A Nectid-originated therapeutic combination concept was developed into a defined intellectual property position, supported by a development rationale framed around the requirements of a strategic counterparty already active in the therapeutic area.
The programme was subsequently transacted to Grünenthal. The work illustrates the sequence Nectid applies: identify the therapeutic opportunity, create a defensible position, define the evidence a specific counterparty would need, and run the process to a decision.
01
Therapeutic Opportunity
02
IP Creation
03
Development Strategy
04
Strategic Counterparty
05
Transaction
Built for Sensitive Business Development.
Engagements routinely involve confidential company information, unpublished data and direct counterparty feedback. Materials are handled on a need-to-know basis, access is limited to the individuals working on the engagement, and counterparty conversations are conducted under agreed confidentiality terms.
Have an Asset Caught
Between Clinical Promise and a Transaction?
That is precisely where TSCIP is designed to operate.